Chanticleer — Sonnet BioTherapeutics Holdings — Investor Presentation (September 2024)
34 slides from Chanticleer's investor presentation, Sep 9, 2024
Slide 1: Corporate Presentation September 2024
fy SONNET BioTherapeutics Corporate Presentation September 2024 sonnetbio.com NASDAQ: SONN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements about Sonnet BioTherapeutics within the meaning of Section 27A of the Secutities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, inclu
Slide 3: Validated albumin-binding approach affords targeted delivery
Validated albumin-binding approach affords targeted delivery with enhanced tumor penetration, retention, and local activation of an immune effect Lead programs designed to address high-value solid tumor markets Demonstrated encouraging results in immune activation and tumor reduction Existing materi
Slide 4: Development Pipeline
Development Pipeline SON-1010(IL12-F,,AB) Solid Tumors a & SON-1010(IL12-F,,AB) Combination Platinum-Resistant & with atezolizumab (Tecentriq?) OvarianCancer(PROC) ° 2 SON-1210(IL12-F,,AB-IL15) Solid Tumors eo 3 - SON-1210(IL12-F,,AB-IL15) Pancreatic Cancer mn AIPSARCOMA co | ic SON-1411 (IL18-F,,AB
Slide 5: FAB Platform Technology Mechanism of Action
FAB Platform Technology Mechanism of Action >) View Video
Slide 6: Fully Human Albumin-Binding Platform
Fully Human Albumin-Binding * (F,,AB®) Platform Yl Fully Modular Technology IL-18 Provides Single or IL-15 Bifunctional Capabilities SON-1010 (IL12-F,,AB) i™ _ ———e | is ™ Se reremre ete aen are IL-12 F.,AB Construct Single Chain Antibody Fragment (scFv) Targets TME while Enhancing PK and Therapeuti
Slide 7: Targeted Delivery with Enhanced Tumor Penetration and Retention
Targeted Delivery with Enhanced Tumor Penetration and Retention F,,AB construct binds to albumin in systemic circulation IFNy upregulates PD-L1 expression on tumor cells, providing a target for checkpoint inhibitors Activation and modulation within the A @ 4 tumor microenvironment Solid tumors secre
Slide 8: Cytokine Payloads with Demonstrated Anti-Tumor Potential
Cytokine Payloads with Demonstrated Anti-Tumor Potential Customizable Platform to Drive Desired Immune Responses 8 SONNET BioTherapeutics IL-12 (Interleukin-12) Activates T cells and NK cells Reducing immunosuppression by conversion of M@2@>M1 Enhancing anti-tumor effects by promoting Th1 differenti
Slide 9: Demonstrated Tumor Uptake and Retention
Demonstrated Tumor Uptake and Retention SPARC-Mediated Binding with Optimized Tumor Retention Using Albumin, Most Abundant Protein in the Blood and Elevated in the TME F,,AB Alone Anti-TGFB, no FyAB Anti-TGFB-F,AB 0-0) 50kD [__> <2 s Results show F,,AB enhanced EPR = Efficacy SONNET BioTherapeutics
Slide 10: Enhanced Pharmacokinetic Characteristics
Enhanced Pharmacokinetic Characteristics F,,AB Has Shown to Extend Plasma Half-Life of Cytokine Payloads IL-12: 4x Improvement IL-15: 10x Improvement -@- IL12-FHAB -@-1L12WT -@-1L15-FHAB -®-IL15WT ' th = —_| > 100,000.00000 . | ——o = ty2B = 9.5 hrs ~e § ty2B ~7.0 hrs g > NN, Fo S MN 8 1,000.00000 |
Slide 11: Validated Approach
Validated Approach Albumin and GP60/SPARC Pathway Validated by Multiple Anti-Cancer Therapies Abraxane’ NANOBODY nanoparticle albumin bound paclitaxel Bivalent anti-RANKL construct Nanobody that binds to Albumin Arer2xig é Prviynx Acquisition in 2010 January 2018 Acquisition sanofi SONNET BioTherape
Slide 12: Targeted Immune Activation
Targeted Immune Activation Cancer Therapy, Turning ‘Cold’ Tumors ‘Hot’ Initially Targeting Solid Tumors and Platinum-Resistant Ovarian Cancer (PROC)
Slide 13: Significant Unmet Need
Significant Unmet Need Current Therapies are Lacking Platinum- No durable responses. 1 7 Recently approved Elahere® only benefits 42% of patients* Resistant Ovarian a y ore Cancer (PROC) Market Opportunity’ 58% of Patients Diagnosed 19,710 sresiviinsigee at Late Stage of Disease with Only a 31% 5-ye
Slide 14: SON-1010 (IL12-FHAB)
SON-1010 (IL12-F,,AB) Ongoing Studies for Solid Tumors and Platinum-Resistant Ovarian Cancer (PROC) Targeted systemic delivery and activation of local immune responses within the tumor microenvironment Material Supply Agreement with Roche for the study of PROC using SON-1010 in Combination with atez
Slide 15: Demonstrated to Reduce Tumor Growth
Demonstrated to Reduce Tumor Growth SON-1010 . (IL12-F,,AB) vs Pieeee a IL-12 Alone in 2500) 1L12-FyAB (1.3ug) t = 2000} te IL-12 (30ug) A Mouse B16F1 0 | ew Melanoma Model ra 1:30 ratio of IL-12 ha ; “+ sf 4 SON-1010 is ~35-Fold pate na More Potent Than ; ; © pa 8 ‘ ‘ IL-12 Alone at Day 10 SONNET B
Slide 16: Development Plan Towards Potential Approval
Development Plan Towards Potential Approval $B221 Phase 1b/2a Ongoing SON-1010 Combo with atezolizumab PROC $B102 Completed / $B101 Late-Stage — Phase 1 Ongoing SON-1010 Monotherapy Solid Tumors SONNET BioTherapeutics Potential Future Potential Future Phase 2b Dose Phase3 Finding Study Study (pop PK
Slide 17: SB101/SB102 Phase 1 Study
SB101/SB102 capo ircs in Healthy Volunteers . 300 ng/kg 300/1200 ng/kg q3wks (© 200ng/kg (@800ng/kg thiL-12) ThiL-12) Dose level 6 ng/kg q3wks ng/kg q3wks Dose level 4 ) Phase 1 Study 100 ng/kg Interim PK Analysis 50 ng/kg and Modeting 6 per cohort Dose Level 1 150/300 ng/kg q3wks Program Highlights
Slide 18: SB101: Phase 1 Study Clinical Benefit
SB101: Phase 1 Study Clinical Benefit Mean Progression Free Survival of 166 Days elke aw z 50 aw 4 7 of 16 (44%) Patients remained stable at 4 months, suggesting clinical benefit or The first patient, whose endometrial sarcoma was progressing at study entry, had smaller tumors and complete resolutio
Slide 19: SB101: Phase 1 Study Immune System Activation
SB101: Phase 1 Study Immune System Activation 1000 IFN-y 400 IL-10 a = 100 2 10 2 2 Increase in key Inflamatory z 10 304 Markers: IFNy, IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, and TNFa 1. I 1-4-7. 1 I 0 7 #14 24 28 35 42 49 56 0 7 #14 21 28 35 42 49 56 Dose-Related, Controlled and Day Pay Prolonged In
Slide 20: SB101/102: Phase 1 Study PK
SB101/102: Phase 1 Study PK Demonstrates Extended Half-Life of IL-12 Mean Half-Life was 113 Hours with SON-1010, Compared to 12 Hours with rhlL-12 Enhanced Dose-Related Single Compartment Kinetics in Cancer Patients Compared to Two Compartments in Healthy Volunteers SB101 PK, Cycle 2 in Cancer @1: 5
Slide 21: SB221: Phase 1b/2 Study
$B221: Phase 1b/2 Study SON-1010 Combination with Atezolizumab in PROC Material Supply Agreement with Roche for atezolizumab (Tecentriq®) Enrolling Subjects with PROC and Have Recurrence Within 6 Months Following Last Dose of a Platinum-Containing Regimen Part 1: * Enrolling: 30-51 Subjects Part 2:
Slide 22: FAB Enabling Technology with Pipeline Expansion Capabilities
FAB Enabling Technology with Pipeline Expansion Capabilities Demonstrating Promising Data in Solid Tumors SONNET BioTherapeutics SON-1210 1L12-F,AB-IL15 SON-1411 1L18-F ,AB-IL12 22
Slide 23: SON-1210: IL12-FHAB-IL15
SON-1210: IL12-FHAB-IL15 Improved Activity on Key Inflammatory IFNy IL12 Combined with IL15 Had Synergistic Effect of IFNy Production’ Lymphoblast proliferation assay (IL-12) IFN-y release assay (IL-12) CTLL-2 proliferation assay (IL-15) 00 2.59 age 1L12-F,,AB-IL15 “@ 1112 (R&D ref) 25000. (R&D ref)
Slide 24: SON-1210: Ongoing Study in Solid Tumors
SON-1210: IL12-FHAB-IL15 Ongoing Study in Solid Tumors 1200: Tumor Volume (mm*) % Inhibition 39% 78% MN% 91% 6 8 10 12 14 16 18 20 22 xo 24 xttt Days oo ~~ - - Tumor Bearing Placebo 1g 1L12-FYAB-IL15 5ug 1L12-F ,AB-IL15 5yg IL15 and IL12 Ref 5 yg 1L12-ABD-IL15 (x3) SONNET BioTherapeutics Cini JK, et
Slide 25: SON-1210: Advancing as Treatment of Pancreatic Cancer
SON-1210: IL12-FHAB-IL15 Advancing as Treatment of Pancreatic Cancer SON-1210: Highly aggressive and often fatal disease First albumin-binding bifunctional IL-12/IL-15 fusion protein, that originates in the pancreas, typically for solid tumor immunotherapy ge tected late due to.vaguelolabsonteatly C
Slide 26: SON-1411: IL18-FHAB-IL12
SON-1411: IL18-F,,AB-IL12 Reduction in Tumor Volume Py ee IFN-y, 1NRe _ 7 IL-18°°R and IL-12 co-activate immune cells ses in the TME SON-1411 Albumin binds to Albumin IL-18 in combination with IL-12 synergistically induces IFNy by activating NK, CD8, and CD4T cells, which upregulates PD-L1 on tumor
Slide 27: SON-1410
SON-1410 IL18-F,,AB-IL12 Bifunctional Interleukins % Inhibition 2100: -@ Tumor Bearing Placebo 25% -® tpg IL18-FYAB-IL12 70% -@ 5ug IL18-FyAB-IL12 40% -@ 5ug IL18 & 5ug IL12 Ref 1800 3 Interleukin Dosing Ratios 1142 @ 0.5ug &1L18 @ 0.1709 600 1112 @2.5ug &1L18 @ 0.850 1L12 @ Sug & 1L18 @ Sug Tumor V
Slide 28: SON-080 (Low-Dose IL-6)
SON-080 (Low-Dose IL-6) Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic \ Peripheral Neuropathy (DPN) Seeking Partnership to Support Phase 2 Trial
Slide 29: SON-080 Encouraging Results from Phase 1b/2a Study in CIPN
SON-080 Encouraging Results from Phase 1b/2a Study in CIPN Randomized, Double-blind, Placebo-controlled Study Interim Analysis 7 FPP APP J 4 i 4 3 4 5 6 7 8 5 10 ii iz 13 14 & 16 24 | 4 | | a oe | | | | | | | | | | | =a T TTT T T T T T T T T T —=— PK/PD in % patients PK/PD in other % patients Screen
Slide 30: IP Portfolio
IP Portfolio F,,AB Platform Twenty (20) total patents— 6 issued SON-080 (Low-dose | L-6) and 14 pending Two patents issued and unexpired - U.S. Composition of matter, formulations, | methods of use and proprietary Three patents filed and pending in manufacturing processes major markets Low-Dose IL-6
Slide 31: Proven Leadership Team
Proven Leadership Team ouTLooK thBristol Myers Squibd™ golgman Genentech “put | -uCL| CHARDAN Ham Jay Cross Pankaj Mohan, Ph.D. Chief Financial Officer Founder, CEO and Chairman Xcellerex —— UNUN cenutecn Lonza Susan Dexter <> Chief Technical Officer SONNET BioTherapeutics ETHICON MEDAREX ORTHOBSO T
Slide 32: Multiple Upcoming Milestones
Multiple Upcoming Milestones Expected to Drive Value Phase 1: Solid Tumors (Monotherapy) oO 5 Safety Data Topline Efficacy Data 7 e 2H24 1H25 2H25 W—¥4H-~—_ @ r Additional Safety Data RP2D & Topline n Phase 1b/2a: PROC (Combo with Atezolizumab) Efficacy Data ° Phase 1: Pancreatic Cancer N 5 IND Subm
Slide 33: Investment Summary
Investment Summary Advancing Targeted Immune Activation Cancer Therapies to Turn ‘Cold’ Tumors ‘Hot’ Q © Fully Modular Technology Lead Programs Demonstrating Multiple Pipeline Expansion Provides Single or Bispecific Encouraging Results in Immune Opportunities Throughout High Payload Applications whi
Slide 34: Thank You!
§ SONNET BioTherapeutics Thank You! ¥ 4 Investor Relations sonnetbio.com JTC Team NASDAQ: SONN ; [email protected]
Sonnet BioTherapeutics Holdings — Investor Presentation (September 2024) on 6ix